Scientists used lipid nanoparticles to deliver CRISPR-Cas9 targeting Hao1 for the treatment of primary hyperoxaluria type 1. Proof-of-concept studies...
YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...
The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...
Researchers in China report pre-clinical in vivo data demonstrating the potential of a non-viral CRISPR-Cas9 therapy to treat primary hyperoxaluria 1....
In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...
YolTech Therapeutics announced last week that the first two patients have been dosed in a Phase 1 trial of YOLT-203, an in vivo CRISPR-based...
